HSIC vs MCK: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
MCK is the larger of the two ($123.64B market cap): the incumbent the market prices for continued execution (20.56x forward earnings, beta 0.28). HSIC is the smaller challenger ($9.75B), cheaper on forward earnings (14.68x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
HSIC vs MCK: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | HSIC | MCK | What it tells you |
|---|---|---|---|
| Market cap | $9.75B | $123.64B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 14.68 | 20.56 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 24.16 | 27.62 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.86 | 0.28 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 83% of range | 87% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Reading it: HSIC is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how HSIC and MCK affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HSIC and MCK share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HSIC and MCK exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Henry Schein (HSIC) do?
Henry Schein sells the products a dental office or a physician's practice consumes every day: consumables, small equipment, implants, orthodontic aligners, endodontic and biomaterial products, plus the software that runs the front desk and the billing. It reports in three pieces. Global Distribution and Value-Added Services is the large, low-margin core that moves other manufacturers' goods to roughly a million customers across dozens of countries. Global Specialty Products covers the higher-margin implant, orthodontic and biomaterials lines the company mostly bought. Global Technology sells practice-management and revenue-cycle software, including the Dentrix family, and carries by far the best economics in the company (segment operating margin of roughly 27% in Q2 2026 on segment operating income of about $49 million). Specialty and technology together contribute around half of operating income on a small fraction of revenue, which is the whole strategic point.
What does McKesson Corporation (MCK) do?
McKesson Corporation is a healthcare-services and pharmaceutical-distribution company, one of the "Big Three" US drug wholesalers alongside Cencora (formerly AmerisourceBergen) and Cardinal Health that together handle the large majority of prescription drugs sold in the country. In fiscal 2026 (ended March 2026) the company reported roughly $403 billion in revenue, and trailing revenue has since reached about $411 billion, the bulk of it from its North American Pharmaceutical segment, which sources, warehouses, and delivers branded, generic, and specialty medicines to pharmacies, health systems, and providers. Because distribution is a scale game with very low margins, McKesson competes on logistics efficiency, breadth of contracts, and reliability rather than pricing power on the drugs themselves.
HSIC vs MCK: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- HSIC drivers: Mix shift toward specialty and technology; The value-creation and restructuring program.
- MCK drivers: Defensive, volume-driven distribution core; Specialty and oncology services mix-shift.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Distribution economics are thin, so a small swing in product mix or in supplier rebates moves earnings more than revenue growth suggests. For MCK, the central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results.
HSIC or MCK: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick HSIC if you believe its drivers more; MCK if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HSIC and MCK guides.
HSIC vs MCK: the full fundamentals
HSIC. At $86.84 against guided non-GAAP EPS of about $5.29 to $5.39, HSIC trades near 16 times this year's adjusted earnings and about 14.5 times next year's consensus, but roughly 25 times trailing GAAP earnings, because restructuring charges running through 2027 keep reported profit well below the adjusted figure. The sales multiple, under 0.75 times, matters least for a distributor. The gap between the GAAP and adjusted multiples is effectively the market's discount on whether the margin program sticks.
MCK. All figures are approximate and tied to the asOf date; verify live numbers before acting. McKesson reports on a fiscal year ending in March, so the June 2026 quarter is fiscal Q1 2027. Revenue multiples mean little here (about 0.28 times sales); at about $1,004 a share the stock trades near 27 times trailing GAAP earnings and 20 times forward estimates, with analysts modeling adjusted EPS of about $44.66 for fiscal 2027 and $50.63 for fiscal 2028.
Headline figures (approximate, October 2026): HSIC shows revenue (ttm) ~$13.6B, up ~6.7% year over year in Q2 2026, margins (ttm) ~31% gross, ~5.8% operating, ~3% net, net income (ttm) ~$403M; GAAP EPS ~$3.43, p/e ~25x trailing GAAP, ~14.5x forward; MCK shows revenue (ttm) ~$411 billion (+7.7% YoY latest quarter), margin profile ~3.6% gross, ~1.35% operating, ~1.1% net (distribution dominates revenue), net income (ttm) ~$4.6 billion, adjusted eps (fiscal q1 2027) ~$9.93 vs ~$9.54 est..
The bottom line: HSIC vs MCK
HSIC and MCK are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HSIC and MCK exposure against your real portfolio. It is not an investment adviser.
Wondering how HSIC or MCK fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Henry Schein
Ask Walnut's AI anything about HSIC and see how it fits what you own.
FAQ
What is the difference between HSIC and MCK?
+
Henry Schein sells the products a dental office or a physician's practice consumes every day: consumables, small equipment, implants, orthodontic aligners, endodontic and biomaterial products, plus the software that runs the front desk and the billing. McKesson Corporation is a healthcare-services and pharmaceutical-distribution company, one of the "Big Three" US drug wholesalers alongside Cencora (formerly AmerisourceBergen) and Cardinal Health that together handle the large majority of prescription drugs sold in the country. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is HSIC or MCK the better stock?
+
Neither is universally better. MCK is the larger incumbent; HSIC is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, HSIC or MCK?
+
On forward P/E (as of November 2026), HSIC trades at 14.68x and MCK at 20.56x, so HSIC is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both HSIC and MCK?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of HSIC vs MCK?
+
HSIC: Distribution economics are thin, so a small swing in product mix or in supplier rebates moves earnings more than revenue growth suggests. Dental consumables and equipment demand depends on discretionary patient visits, and the softness that started in 2023 has not fully cleared. Tariffs and freight on imported dental and medical goods are a live cost input that cannot always be passed through quickly. The company has grown specialty and technology largely by acquisition, which carries integration risk and a large goodwill balance relative to equity. Manufacturers selling directly to practices, and pure-play e-commerce suppliers, continue to chip at the intermediary's role, and the 2023 cyberattack is a reminder of how concentrated the operational risk in an ordering platform can be. Leverage is not trivial either: Yahoo data show ~$3.8 billion of debt against ~$157 million of cash, and GAAP net margin of roughly 3% leaves little cushion. A CFO handover on November 4, 2026, the day after Q3 results, adds execution risk during the margin program. MCK: The central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results. Customer concentration is real, with a few very large retail-pharmacy customers representing a big share of revenue, giving those partners negotiating leverage. Drug-pricing politics and policy (Medicare negotiation, PBM reform, importation proposals) create ongoing regulatory uncertainty. McKesson also carries a legacy of multibillion-dollar opioid-distribution settlements, and future litigation or regulatory action remains a tail risk. Execution on the Medical-Surgical separation, on integrating oncology and specialty acquisitions, and on the Option Care Health partnership adds transition risk on top of the steady core. GAAP earnings can also swing well away from adjusted figures: GAAP net income was about $614 million in the June 2026 quarter versus about $1.68 billion in the March quarter. Valuation has stretched as well, with the shares up about 21% in three months to above $1,000 and trading near 27 times trailing GAAP earnings.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell HSIC or MCK; figures are approximate and dated (as of November 2026). Verify current data before investing.